A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo

In vivo genome editing using Staphylococcus aureus Cas9

Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687

Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering

Wright, A. V., Nuñez, J. K., & Doudna, J. A. (2016) · Cell · doi:10.1016/j.cell.2015.12.035 · Cited by 989

HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B

Nassal, M. (2015) · Gut · doi:10.1136/gutjnl-2015-309809 · Cited by 932

Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo

Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876

The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo

Lin, S.-R., Yang, H.-C., Kuo, Y.-T., Liu, C.-J., Yang, T.-Y., Sung, K.-C., Lin, Y.-Y., Wang, H.-Y., Wang, C.-C., Shen, Y.-C., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.38 · Cited by 386

Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection

Yang, P. L., Althage, A., Chung, J., & Chisari, F. V. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202398599 · Cited by 381

CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Ramanan, V., Shlomai, A., Cox, D. B. T., Schwartz, R. E., Michailidis, E., Bhatta, A., Scott, D. A., Zhang, F., Rice, C. M., & Bhatia, S. N. (2015) · Scientific Reports · doi:10.1038/srep10833 · Cited by 312

An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo

Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261

Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication

Dong, C., Qu, L., Wang, H., Wei, L., Dong, Y., & Xiong, S. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.03.015 · Cited by 245

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

Zhen, S., Hua, L., Liu, Y.-H., Gao, L.-C., Fu, J., Wan, D.-Y., Dong, L.-H., Song, H.-F., & Gao, X. (2015) · Gene Therapy · doi:10.1038/gt.2015.2 · Cited by 215

DMSO increases efficiency of genome editing at two non-coding loci

Stratigopoulos, G., Rosa, M. C. D., LeDuc, C. A., Leibel, R. L., & Doege, C. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198637 · Cited by 15

Treatments for HBV: A Glimpse into the Future

Bartoli, A., Gabrielli, F., Tassi, A., Cursaro, C., Pinelli, A., & Andreoné, P. (2021) · Viruses · doi:10.3390/v13091767 · Cited by 16

A brief review of mRNA therapeutics and delivery for bone tissue engineering

Rajendran, A. K., Amirthalingam, S., & Hwang, N. S.-Y. (2022) · RSC Advances · doi:10.1039/d2ra00713d · Cited by 16

Triple‐Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases

Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019) · Angewandte Chemie · doi:10.1002/ange.201903618 · Cited by 15

Engineering CRISPR-Cas9 RNA–Protein Complexes for Improved Function and Delivery

Rouet, R., de Oñate, L., Li, J., Murthy, N., & Wilson, R. C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0037 · Cited by 16

Combination of Genetics and Nanotechnology for Down Syndrome Modification: A Potential Hypothesis and Review of the Literature

Tafazoli, A., Behjati, F., Farhud, D. D., & Abbaszadegan, M. R. (2019) · Iranian Journal of Public Health · doi:10.18502/ijph.v48i3.878 · Cited by 15

Supramolecular Nanosubstrate‐Mediated Delivery for CRISPR/Cas9 Gene Disruption and Deletion

Ban, Q., Yang, P., Chou, S., Qiao, L., Xia, H., Xue, J., Wang, F., Xu, X., Sun, N., Zhang, R. Y., et al. (2021) · Small · doi:10.1002/smll.202100546 · Cited by 16

Co-delivery of mRNA and SPIONs through amino-ester nanomaterials

Luo, X. L., Zhao, W., Li, B., Zhang, X., Zhang, C., Bratasz, A., Deng, B., McComb, D. W., & Dong, Y. (2018) · Nano Research · doi:10.1007/s12274-018-2082-0 · Cited by 15

Engineering stimuli-responsive nanocarriers for CRISPR/Cas9 genome editing: next-generation cancer therapeutics

Mehnath, S. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf127 · Cited by 14

Gene editing in common cardiovascular diseases

Lauerer, A.-M., Caravia, X. M., Maier, L. S., Chemello, F., & Lebek, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108720 · Cited by 15

Targeting HBV cccDNA Levels: Key to Achieving Complete Cure of Chronic Hepatitis B

He, W., Zheng, Z., Zhao, Q., Zhang, R., & Zheng, H. (2024) · Pathogens · doi:10.3390/pathogens13121100 · Cited by 14

Construction of Messenger RNA (mRNA) Probes Delivered By Lipid Nanoparticles to Visualize Intracellular Protein Expression and Localization at Organelles

Zhao, W., Zeng, C., Yan, J., Du, S., Hou, X., Zhang, C., Li, W., Deng, B., McComb, D. W., Xue, Y., et al. (2021) · Advanced Materials · doi:10.1002/adma.202103131 · Cited by 14

Nanoparticles‐Mediated CRISPR/Cas Gene Editing Delivery System

Saw, P. E., Cui, G., & Xu, X. (2022) · ChemMedChem · doi:10.1002/cmdc.202100777 · Cited by 14

Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment

Wang, S., Zhu, Y., Du, S., & Zheng, Y. (2024) · Cells · doi:10.3390/cells13070568 · Cited by 16

PCSK9 inhibition 2018: riding a new wave of coronary prevention

Ward, N. C., Page, M. M., & Watts, G. F. (2019) · Clinical Science · doi:10.1042/cs20171300 · Cited by 13

A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice

Li, M., Huang, Y., Wu, J., Li, S., Mei, M., Chen, H., Wang, N., Wu, W., Zhou, B., Tan, X., et al. (2022) · Materials Horizons · doi:10.1039/d2mh01260j · Cited by 13

siRNA nanotherapeutics: a promising strategy for anti‐HBV therapy

Aghamiri, S., Jafarpour, A., Gomari, M. M., Ghorbani, J., Rajabibazl, M., & Payandeh, Z. (2019) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2018.5286 · Cited by 14

A Broad Application of CRISPR Cas9 in Infectious Diseases of Central Nervous System

Bellizzi, A., Ahye, N., Jalagadugula, G. S., & Wollebo, H. S. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09878-7 · Cited by 12

Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication

Khanal, S., Cao, D., Zhang, J., Zhang, Y., Schank, M., Dang, X., Nguyen, L. N. T., Wu, X. Y., Jiang, Y., Ning, S., et al. (2022) · Viruses · doi:10.3390/v14091902 · Cited by 10

CRISPR/Cas9: A Potential Life-Saving Tool. What’s next?

Gulei, D., & Berindan‐Neagoe, I. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.10.013 · Cited by 12

Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia

Damase, T. R., Sukhovershin, R. A., Godin, B., Nasir, K., & Cooke, J. P. (2024) · Circulation · doi:10.1161/circulationaha.123.067957 · Cited by 11

PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication

Gao, L., Yang, J., Feng, J.-T., Liu, Z., Dong, Y., Luo, J., Yu, L., Wang, J., Fan, H., Ma, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.856463 · Cited by 10

The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy

Li, Z.-F., & Wu, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.911429 · Cited by 11

Hepatitis B virus: promising drug targets and therapeutic implications

Maepa, M. B., Bloom, K. M., Ely, A., & Arbuthnot, P. B. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1915990 · Cited by 10

Genome editing: An essential technology for cancer treatment

Tufail, M. (2022) · Medicine in Omics · doi:10.1016/j.meomic.2022.100015 · Cited by 10

Knockout of cytidine monophosphate-N-acetylneuraminic acid hydroxylase in Chinese hamster ovary cells by CRISPR/Cas9-based gene-editing technology

Chai, Y., Cao, X.-X., Ge, M.-M., Mi, C., Guo, X. H., & Wang, T. (2020) · Biochemical Engineering Journal · doi:10.1016/j.bej.2020.107663 · Cited by 9

Inorganic smart nanoparticles: a new tool to deliver CRISPR systems into plant cells

Mostafa, M., Ahmed, F. K., Alghuthaymi, M. A., & Abd-Elsalam, K. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821910-2.00036-9 · Cited by 9

Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles

Li, S., Du, M., Deng, J., Deng, G., Li, J., Song, Z., & Han, H. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.10.015 · Cited by 10

Synthetic nanoparticles for the delivery of CRISPR/Cas9 gene editing system: classification and biomedical applications

Zheng, Q., Wang, W., Zhou, Y., Mo, J., Chang, X., Zha, Z., & Zha, L. (2023) · Biomaterials Science · doi:10.1039/d3bm00788j · Cited by 10

CRISPR/Cas9 in cancer: An attempt to the present trends and future prospects

Kaligotla, V. S. A., Jasti, T., & Kandra, P. (2021) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2200 · Cited by 8

CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers

Kostyushev, D. S., Kostyusheva, A., Ponomareva, N. I., Brezgin, S., & Chulanov, V. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0075 · Cited by 8

Challenges and Future Prospects of CRISPR Technology

Khan, Z., Khan, S. H., & Ahmad, A. (2021) · Springer eBooks · doi:10.1007/978-981-16-6305-5_10 · Cited by 9

Targeting Hepatitis B Virus DNA Using Designer Gene Editors

Zhang, H., & Tu, T. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.05.006 · Cited by 8

Screening lipid nanoparticles using DNA barcoding and qPCR

Liu, D., Wang, X., Xu, L., Al-Delfi, Z., Mekonnen, Z. A., Gao, S., Grubor‐Bauk, B., & Zhao, C. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114598 · Cited by 8

Strategies to Eliminate HBV Infection: an Update

Tang, L., Kottilil, S., & Wilson, E. M. P. (2020) · Future Virology · doi:10.2217/fvl-2019-0133 · Cited by 8

Frontiers of CRISPR-Cas9 for Cancer Research and Therapy

Banerjee, A., Malonia, S. K., & Dutta, S. (2021) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2020.00033 · Cited by 9

RIPK1 regulates cell function and death mediated by UVB radiation and TNF-α

Zhao, Y., Chen, Y., Li, X., Sun, Y., Shao, Y., Zhang, Y., & Liu, Z. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.04.024 · Cited by 8

Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases

Jacobs, R., Singh, P., Smith, T. S., Arbuthnot, P. B., & Maepa, M. B. (2022) · Gene Therapy · doi:10.1038/s41434-022-00342-5 · Cited by 7

CRISPR-Cas9 gene editing and human diseases

Jinka, C. (2022) · Bioinformation · doi:10.6026/973206300181081 · Cited by 6

A review of CRISPR Cas9 for ASCVD: treatment strategies and could target PSCK9 gene using CRISPR cas9 prevent the patient from atherosclerotic vascular disease?

Suwito, B. E., Adji, A. S., Wardani, V. A. K., Widjaja, J. S., Angel, S. C. S., & Rahman, F. S. (2022) · Bali Medical Journal · doi:10.15562/bmj.v11i2.3414 · Cited by 6

Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness

Asaikkutti, A., Vimala, K., Dhineshkumar, E., Cheruparambath, P., Balakrishnan, K., & Arul, V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104567 · Cited by 7

Recent Advances in Therapeutic Genome Editing in China

Yang, Y., Wang, Q., Li, Q., Men, K., He, Z., Deng, H., Ji, W., & Wei, Y. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.210 · Cited by 6

Endosomal Escapable and Nuclear Localizing Cationic Polyaspartate-Based CRISPR Activation System for Preventing Respiratory Virus Infection by Specifically Inducing Interferon-λ

Liu, S., Deng, S., Li, M., Chen, J., Yuan, Y., Zhao, H., Zhou, J., Wang, J., Zhang, H., & Cheng, D. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c16588 · Cited by 5

Advances in Nanocarriers for Delivering Therapeutic Agents Against Hepatitis B Virus

Li, J., Yuan, J., Li, H., Guo, J., Li, M., Zhang, T., Liang, X., Fan, H., & Liu, X. (2024) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300132 · Cited by 5

An Overview of Genome Editing in Cardiovascular and Metabolic Diseases

Musunuru, K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_1 · Cited by 5

CRISPR system for genome engineering: the application for autophagy study

Cui, J., Chew, S. J. L., Shi, Y. P., Gong, Z., & Shen, H. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.5.044 · Cited by 7

A Multifunctional and Highly Adaptable Reporter System for CRISPR/Cas Editing

Wettengel, J. M., Hansen-Palmus, L., Yusova, S., Rust, L. N., Biswas, S., Carson, J. N., Ryu, J., Bimber, B. N., Hennebold, J. D., & Burwitz, B. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098271 · Cited by 6

Therapeutic interventions aimed at cccDNA: unveiling mechanisms and evaluating the potency of natural products

Hao, L., Li, S., & Hu, X. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1598872 · Cited by 4

Advancements in Nonviral Gene Editing Strategies for Rare Diseases

Pérez-Maroto, J., Sepp‐Lorenzino, L., Castaño-Esteban, D., Palacios, D., & Sot, B. (2025) · Human Gene Therapy · doi:10.1177/10430342251372056 · Cited by 6

Antiviral Activity of CRISPR/Cas9 Ribonucleoprotein Complexes on a Hepatitis B Virus Model In Vivo

Kostyusheva, A., Brezgin, S., Ponomareva, N. I., Goptar, I. A., Nikiforova, A., Gegechkori, V., Poluektova, V. B., Turkadze, K. A., Sudina, A., Chulanov, V., et al. (2022) · Molecular Biology · doi:10.1134/s0026893322060097 · Cited by 4

In vivo Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update

Kayesh, M. E. H., Hashem, M. A., Kohara, M., & Tsukiyama–Kohara, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.953218 · Cited by 4

Intravaginal delivery for CRISPR–Cas9 technology: For example, the treatment of HPV infection

Zhen, S., Chen, H., Lu, J., Yang, X., Tuo, X., Chang, S., Tian, Y., & Li, X. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28552 · Cited by 5

Suppression of HBV replication and expression by CRISPR/Cas9 ribonucleoproteins

Hill, A. C., Schank, M., Zhang, Y., Sun, N., Wang, L., Zhao, J., Banik, P., Pyburn, J. S., Orfield, H. K., Lightner, J., et al. (2025) · Antiviral Research · doi:10.1016/j.antiviral.2025.106326 · Cited by 3

Extracellular Vesicle-Mediated CRISPR/Cas Delivery: Their Applications in Molecular Imaging and Precision Biomedicine

Bingxue, D., Wenchao, L., & Xing, B. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_74-1 · Cited by 3

Recent Advancement and Innovations in CRISPR/Cas and CRISPR Related Technologies: A review

Khan, S. H. (2021) · Biotechnology and Bioprocessing · doi:10.31579/2766-2314/042 · Cited by 3

Polymer-Mediated Delivery of CRISPR-Cas9 Genome-Editing Therapeutics for CNS Disease

Iqbal, S., Alexander-Bryant, A. A., & Larsen, J. (2022) · Springer eBooks · doi:10.1007/978-3-031-11409-0_6 · Cited by 3

Design and Update of Multifunctional Polypeptides and Their Applications for the Prevention of Viral Infections and Cancer Immunotherapies

Chen, Y., Song, Y., Zhu, X., Dong, C., & Chen, M.-S. (2023) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2023.2281462 · Cited by 3

Genetic modification of mice using CRISPR-Cas9: Best practices and practical concepts explained

Hosur, V., Low, B. E., & Wiles, M. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-817218-6.00018-8 · Cited by 3

Transient Macrophage Depletion Circumvents Scavenging and Redirects Biodistribution of mRNA-Lipid Nanoparticles

Yuan, Z., Luozhong, S., Li, R., Gu, W., Chen, Y., Bhashyam, D., Lai, R., & Jiang, S. (2025) · ACS Nano · doi:10.1021/acsnano.5c02001 · Cited by 6

Newborn Intravenous Injection of Liposomal CRISPR/Cas9 Complex Has No Incidence of Off-Targets or Tumors in Mice

de Barros, V. M., Flores, L. C. B., Lopes, M., Fachel, F. N. S., Martins, G. R., Siebert, M., Carniel, W. D. S., Garcez, T. N. A., Teixeira, H. F., Matte, Ú. D. S., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050656 · Cited by 2

Lipid Nanoparticles Delivery of CRISPR/Cas9 Targeting PCSK9 and ANGTPL3 as New Therapeutic Gene Editing Modalities for Potential Long-Lasting Treatment Of Dyslipidemia

Syaharani, R., Adhima, F., Amru, S. N., & I’tishom, R. (2021) · International Journal of Research Publications · doi:10.47119/ijrp100921120222750 · Cited by 2

Stochastic Packaging of Cas Proteins into Exosomes

Ponomareva, N. I., Brezgin, S., Kostyusheva, A., Slatinskaya, O. V., Олеговна, Б. Е., Gordeychuk, I. V., Maksimov, G. V., Sokolova, D. V., Babayeva, G. A., Khan, I. I., et al. (2024) · Molecular Biology · doi:10.1134/s0026893324010102 · Cited by 2

Grand Challenges in Gene and Epigenetic Editing for Neurologic Disease

Segal, D. J. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2019.00001 · Cited by 2

CRISPR/Cas-based diagnosis and treatment of infectious diseases

Wang, X., Lǐ, Y., & Huang, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00077-0 · Cited by 1

Advanced drug delivery systems for enhancing the efficacy of RNA-based therapeutics

Alhabib, N. A., Almaniea, M. A., Alehaidib, S. M., Almansour, M. A., Aldosary, M. S., Almegbel, M. T., Alsubaie, S. A., & Alzahrani, A. M. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns10.15029 · Cited by 1

2-((Diphenylmethylene)amino)ethyl N-(Cyclohexyl)carbamate

Baxter, B. N., Marmande, M. H., Albers, A., Gangasani, M. R., Le, H. N., Molokhia, O. E., Monteiro-Pai, J., Ransom, K. V., & Forbes, D. C. (2025) · Molbank · doi:10.3390/m1947 · Cited by 1

A Galactose‐Engineered Dual‐Responsive Nanocarrier for ASO/CRISPR‐Cas9 Delivery to Inhibit HBV Replication

Chen, L., Huang, Q., Liu, Y., Chen, K., Yang, Q., Tang, H., Wang, D., & Tang, Z. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502835 · Cited by 4

Research progress of LNP-based mRNA delivery system in the treatment of liver disease

Wang, R., Tian, C., Ji, E., Wu, Q., Wang, J., & Xu, T. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112138 · Cited by 1

Ionizable lipids as a promising platform for creating mRNA vaccines

Milagina, S. V., & Puchkov, P. A. (2026) · Fine Chemical Technologies · doi:10.32362/2410-6593-2026-21-1-51-72 · Cited by 1

Application of CRISPR-Cas9 gene editing to treat HBV

Yan, K., Chen, Y., Feng, J., & Xiong, Y. (2019) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/n972019-00280

Role of Nanotechnology in Diagnosing, Safeguarding, and Treating COVID-19

de Silva, R. M., Hulugalla, K., Ranasinghe, P. R. P., Williams, G. R., & de Silva, K. M. N. (2023) · Maǧallaẗ ǧāmiʿaẗ al-Sulṭān Qābūs li-l-ʿulūm/Sultan Qaboos University journal for science · doi:10.53539/squjs.vol28iss1pp25-41 · Cited by 1

Application of CRISPR-Cas System in the Treatment of Human Viral Disease

Lin, W. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20235902003 · Cited by 1

Biomolecular Therapeutics for HIV

Li, S., & Burnett, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-50878-0.00018-5 · Cited by 1

Delivery Methods for CRISPR/Cas Reagents

Ashraf, S., Munawar, N., Zahoor, M. K., Jamil, A., Hammad, M., Ghaffar, A., & Ahmad, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-6305-5_4 · Cited by 1

Therapeutic Applications of CRISPR/Cas9 Technology for Infectious Diseases

Sharma, G., Rehman, S., & Sharma, A. R. (2022) · Springer eBooks · doi:10.1007/978-981-16-9190-4_25 · Cited by 1

Targeted Therapeutics for Rare Disorders

Keeling, K. M., Leier, A., Bedwell, D. M., Chen, A. T., Kesterson, R. A., Marquez‐Lago, T. T., Müller, U. F., Zhou, J., Popplewell, L. J., & WALLIS, D. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00009-5 · Cited by 1

Lipid nanoparticles for delivery of gene editing components

Kang, D. D., & Dong, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822425-0.00096-8 · Cited by 1

Application of CRISPR/Cas9 in Treating Hepatitis B Virus

Cho, J. (2017) · Journal of Liver Cancer · doi:10.17998/jlc.17.2.111

CRISPR/Cas9技术在生物医学领域的非病毒及病毒载体

秦, 舟., 门, 可., 徐, 珽., 何, 治., 魏, 于., & 杨, 阳. (2017) · Scientia Sinica Vitae · doi:10.1360/n052017-00202

Synthetic mRNA Gene Therapies and Hepatotropic Non-viral Vectors for the Treatment of Chronic HBV Infections

Kairuz, D., Singh, P., Smith, T. S., Arbuthnot, P. B., Ely, A., & Bloom, K. M. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_8

Extracellular Vesicle-Mediated CRISPR/Cas Delivery: Their Applications in Molecular Imaging and Precision Biomedicine

Bingxue, D., Wenchao, L., & Xing, B. (2023) · Springer eBooks · doi:10.1007/978-981-16-1313-5_74-2

Extracellular Vesicle-Mediated CRISPR/Cas Delivery: Their Applications in Molecular Imaging and Precision Biomedicine

Bingxue, D., Wenchao, L., & Xing, B. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_74

CRISPR workflow solutions: Cargos and versatile delivery platforms in genome editing

Munir, A., Ali, M. A., Qari, S. H., Munawar, N., Saleem, M. S., & Ahmad, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13229-2.00014-4

Stochastic packaging of Cas proteins into exosomes

Ponomareva, N. I., Brezgin, S., Kostyusheva, A., Slatinskaya, O. V., Олеговна, Б. Е., Gordeychuk, I. V., Maksimov, G. V., Sokolova, D. V., Babayeva, G. A., Khan, I. I., et al. (2024) · Molecular Biology · doi:10.31857/s0026898424010166

Therapeutic Gene Editing

Zhang, C., Li, H., Bidasee, K. R., Gendelman, H. E., & Dash, P. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_55

Suppression of Hbv Replication and Expression by Crispr/Cas9 RibonucleoproteinsPreprint

Yao, Z., Hill, A. C., Schank, M., Zhang, Y., Wang, L., Zhao, J., Banik, P., Pyburn, J. S., Orfield, H. K., Lightner, J., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5373096

Optimized delivery of dual-gRNA CRISPR/Cas9 via FolicPolySpermine nanoparticles for MHC class I elimination through B2M gene knockout

Khamirani, H. J., Aghasipour, M., Khoddam, S., Shiri, A., Heli, H., Ranjbar, M., Khamirani, M. J., Zoghi, S., Dianatpour, M., & Dastgheib, S. A. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102350

Status and outlook of mRNA therapeutics for viral diseases

Pan, Q., Wang, W., Hl, J., & Zhong, Z. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00390-z

Fast mRNA delivery in vitro and in vivo enabled by magnetic responsive lipid nanoparticles

Lin, Y., Wu, J., Liu, Z., Song, R., Li, Z., Zhang, R., & Li, B. (2026) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-026-01690-1

Aptamers in Osteosarcoma: New Paths for Diagnosis and Treatment

Awad, G., Boutros, M., Chartouni, A., & Pretell-Mazzini, J. (2026) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206398665251010093110

Effets antiviraux de l'agonisation des Toll-like Récepteurs dans les cellules du foie, une nouvelle stratégie immunothérapeutique dans la lutte contre HBV

Aillot, L. (2018) · doi:10.70675/0bd0a765z26cez40d0za0b0zfc717b51698e

Development of a new therapeutic approach based on peptide nanoparticles delivering CRISPR-Cas9 for the specific targeting of KRAS mutations

Gonzalez, V. G. (2023) · theses.fr (ABES) · doi:10.70675/f8c09968z97c4z4635za591z74bf90b6fe70

The CRISPR/Cas technology landscape: From molecular mechanisms to multidisciplinary applications

Liu, Z., Yang, Y., Li, Z., Li, P., Jia, J., Qiao, X., Su, Y., Qin, Y., Wang, H., Dai, Y., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102484

CRISPR/Cas based genome editing for liver diseases: Promise and challenge

Guan, J., Yang, M., Yang, X., He, Q., Wang, B., & Zhan, C. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.09.027

Efficient Generation of Single- and Multigene CRISPR-Cas9 Knockout in Human Cells

Manzoor, Y., Bejaoui, Y., Ramotar, D., & Aouida, M. (2026) · DNA and Cell Biology · doi:10.1177/10445498261495808

BindingDB Entry 50008625: Small molecules as inhibitors of PCSK9: Current status and future challenges.

BindingDB (2021) · UC San Diego · doi:10.7270/q2j38wzz

Optimization of lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes for in vivo delivery of a CRISPR/Cas9 system targeting hepatitis B virus

Akhter, R., Kitab, B., Kayesh, M. E. H., Shimizu, R., Onuma, H., Yamamoto, N., Ogawa, S., Sugiyama, M., Tanaka, Y., Sato, Y., et al. (2025) · Virus Research · doi:10.1016/j.virusres.2025.199682 · Cited by 1

Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA

Kayesh, M. E. H., Amako, Y., Hashem, M. A., Murakami, S., Ogawa, S., Yamamoto, N., Hifumi, T., Miyoshi, N., Sugiyama, M., Tanaka, Y., et al. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198191 · Cited by 39

In vivo Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update

Kayesh, M. E. H., Hashem, M. A., Kohara, M., & Tsukiyama–Kohara, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.953218 · Cited by 4

Preparation of nanoparticles for hepatitis B viral therapy

Kružíková, Z. (2018) · Digital Repository (National Repository of Grey Literature)

CRISPR-Cas9 System In Vivo Delivery to Combat HBV

Ali, J., Aslam, H., & Yousuf, A. (2023) · BIOEDUSCIENCE · doi:10.22236/jbes/12693 · Cited by 1